Evaluation of clinical trials of the plants, which have ethnobotanical uses for skin disorders in Turkey: a review

Zinar Alan¹*, Halil Özgüldü¹, Meryem Sedef Erdal², Ayşenur Yaman Bucak³, A. Yağız Üresin³ and Emine Akalin¹

Abstract

Background: Ethnobotanical studies investigating a large number of traditional herbs and uses have an important role in the discovery of new drugs. Nowadays, some of these traditional herbs are researched directly in the clinical trials. In this study, it is aimed to evaluate the 19 plant species that have been identified in the clinical trials among 300 plant species belonging to 79 families with traditional use for skin problems in Turkey.

Main body: Natural sources are very important to treat diseases for thousands of years. The ethnopharmacological research of natural products ranges from the collection of biogenic samples such as plants to preclinical and clinical studies with the aim of developing drug templates or new drugs. In the ethnopharmacological approach, it is aimed to reach the result based on the traditional and modern knowledge about natural resources. The biggest advantage of this approach is synthesizing new and old information. After the plant or natural compound is determined, other processes work similarly with conventional drugs.

Methods: Ethnobotanical papers, thesis and projects in Istanbul University Faculty of Pharmacy Department of Pharmaceutical Botany and databases (PubMed and Google Scholar) have been sought and results were synthesized.

Results: Most of the clinical uses of herbs have been seen similar to their traditional uses. On the other hand, there are some plants on which their clinical uses differ from the traditional uses such as Borago officinalis, Calendula officinalis or Euphorbia peplus. When the frequency of traditional uses of herbs are compared, Plantago species, Plantago major and Plantago lanceolata are the most used taxa in Turkey, secondly, Hypericum perforatum comes. However, Plantago species are not of much interest in clinical trials. It is seen that most of the plants in the clinical research are tried for wound healing occurring due to different origins such as cancer, surgery and injury. Side effects were observed only during the application of Allium cepa, Cydonia oblonga and H. perforatum.

Conclusions: When clinical trials are evaluated in terms of efficacy and overall results, significant differences and effective results are seen in treatment groups given herbs in comparison with placebo or control groups.

Keywords: Ethnobotany, Skin diseases, Clinical trials, Medicinal plants

* Correspondence: zinar.alan@istanbul.edu.tr

¹Department of Pharmaceutical Botany, Istanbul University Faculty of Pharmacy, 34116 Istanbul, Turkey

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
**Introduction**

Numerous investigations depend on ethnopharmacological approaches have been carried out about medicinal plants and their bioactive compounds via using various different concepts and methods. These multidisciplinary researches concerned with the observation, description and experimental investigations are ranging from anthropology to various fields such as pharmaceutical botany, pharmacognosy, pharmacology, natural product chemistry, toxicology, pharmaceutics, clinical research, and molecular biology [1].

The best known modern drugs such as morphine, codeine, papaverine (Papaver somniferum L.), atropine (Atropa belladonna L.), quinine (Cinchona succirubra Pav), colchicine (Colchicum autumnale L.) and digitalis glycosides (Digitalis purpurea L.) were discovered at the end of these studies.

As an interesting example, it is also listed in our article, the species of Euphorbia peplus L (garden spurge or petty spurge) which is traditionally used for a number of skin problems like warts could be a novel anticancer agent for skin cancers in future [2].

The skin is the largest sensory and contact organ in the human body. It is composed of two layers: the epidermis and the dermis. The skin serves not only to protect the body from the external environment but also to prevent loss of water from the body. The outermost layer of the skin, the stratum corneum, acts as the primary permeability barrier [3].

There are many types of skin conditions that have a tremendous impact on human health and quality of life, including acne, psoriasis, dermatitis, chronic wounds, and infections. The majority of these skin diseases could be treated topically as shown in Table 1, thereby avoiding the potential for systemic side effects [4, 5].

In addition to the above mentioned first-line therapies, there has been a resurgence of the use of ethnobotanical remedies in recent years. Herbal therapies have been tried for the treatment of skin conditions for centuries in the world. Many plants and their extracts have been used traditionally for the management and treatment of various skin disorders. The aim of this paper is to compare the traditional uses of Turkey’s wild plants which are used by local people for the treatment of skin disorders with their clinical trials.

**Methods**

The study consists of two stages, screening of ethnobotanical studies and determination of plants tried in clinical studies for skin problems. In the evaluation, firstly their suitability for traditional use was reviewed in detail. Then, clinical studies were evaluated according to the criteria of Patient population, Design, and Intervention, Outcomes, Efficacy and Safety/ Tolerability.

We assessed the significance of the results of clinical trials with \( p \)-value (\( p < 0.05 \) values are significant) and the healing percentage (complete healing is significant). The study includes randomized, non-randomized, double-blinded, single-blinded, non-blinded, and placebo-controlled clinical studies. However, non-randomized and non-blinded studies can give us limited results.

**Table 1** Common skin disorders and existing topical treatment options

| Skin Disease          | Short Description                                                                 | Topical Treatment                                |
|-----------------------|-----------------------------------------------------------------------------------|--------------------------------------------------|
| Atopic dermatitis     | Atopic dermatitis is the most common type of eczema. It typically begins in childhood and it is a severe, chronic, and pruritic inflammatory skin disease. | Corticosteroids                                   |
|                       |                                                                                   | Calcineurin inhibitors                            |
|                       |                                                                                   | Antimicrobials and antibiotics                    |
|                       |                                                                                   | Antihistamines                                    |
| Psoriasis             | Chronic, immune-mediated skin disease that shows red and scaly patches on the skin that itch or burn. | Corticosteroids                                    |
|                       |                                                                                   | Retinoids                                         |
|                       |                                                                                   | Calcineurin inhibitors                            |
| Acne vulgaris         | Acne is caused by follicular epidermal hyperproliferation and abnormal sebum production within pilosebaceous units in the skin. The most important pathogens linked to acne-prone skin are Propionibacterium acnes, Staphylococcus aureus and Staphylococcus epidermidis | Antibiotics                                       |
| Acute and chronic    | Wound healing is a complex and dynamic process of replacing devitalized and missing cellular structures and tissue layers. Delayed acute wounds and chronic wounds frequently enter a state of pathologic inflammation due to a postponed, incomplete, or uncoordinated wound healing process. | Silver sulfadiazine                                |
| wounds                |                                                                                   | Corticosteroids                                    |
|                       |                                                                                   | Antiseptics                                       |
|                       |                                                                                   | Analgesics                                        |
|                       |                                                                                   | Antimicrobials                                    |
| Fungal infections     | Fungal infections can be classified as superficial fungal infections that affect the skin, nails, hair or mucous membranes, and systemic infections affecting the whole body. | Polyenes                                          |
|                       |                                                                                   | Azoles                                            |
|                       |                                                                                   | Allylamines                                       |
|                       |                                                                                   | Benzylamines                                      |
|                       |                                                                                   | Morpholines                                       |
All documents have been sought on Pubmed and Google Scholar, thesis and projects in IU Faculty of Pharmacy Department of Pharmaceutical Botany.

Results and discussion
A total of 300 medicinal plants belonging to 79 families have been compiled from the research areas in Turkey as shown in Table 2. The family Asteraceae, in the first rank, is the largest family which includes the most species in the world and Turkey. Although the family Lamiaceae, in the second, is not the second largest family in Turkey, it has very important medicinal and aromatic plants in the Mediterranean phytogeographic area. Considering the species, it could be to evaluate Plantago species, P. major and P. lanceolata, which are first in the most used taxa ranking, as the same plant. Because these species are used with a similar name and in a similar way without distinguishing. Then, H. perforatum comes as one of the most used species for skin problems in Turkey.

In the following table, 19 plant species on which their clinical studies are arranged alphabetically. The botanical names are followed by the family names, a Turkish name, traditional uses, and differentiations between clinical and traditional uses of 19 plants as shown in Table 3. In the last part, these clinical studies are summarized as shown in Table 4.

| Table 2 | Families and species of the plants are compiled from research areas |
|---------|---------------------------------------------------------------|
| Total Family | 79 |
| Total Species | 300 |
| The most frequently families | Number of species |
| Asteraceae | 40 |
| Lamiaceae | 25 |
| Scrophulariaceae | 17 |
| Rosaceae | 17 |
| Boraginaceae | 11 |
| Euphorbiaceae | 11 |
| The most frequently taxa | Number of studies |
| Plantago major L. (Plantaginaceae) | 15 |
| Plantago lanceolata L. (Plantaginaceae) | 14 |
| Hypericum perforatum L. (Hypericaceae) | 11 |
| Malva sylvestris L. (Malvaceae) | 9 |
| Malva neglecta Wallr. (Malvaceae) | 9 |
| Allium cepa L. (Liliaceae) | 7 |
| Allium sativum L. (Liliaceae) | 7 |
| Rosa canina L. (Rosaceae) | 7 |
| Urtica dioica L. (Urticaceae) | 6 |
| Rubus sanctus Schreber (Rosaceae) | 6 |

Especially, when we compare the healing efficacy of herbs or their mixtures considering complete healing response, p values, and methods, these could be more effective than others for their special clinical uses of skin disorders: Ankaferd Blood Stopper (Vitis vinifera, Urtica dioica, Glycyrrhiza glabra, Alpinia officinarum, Thymus vulgaris), Calendula officinalis and H. perforatum. Additionally, we have known that these herbs have been used by Turkish traditional medicine for many years. Unfortunately, all herbs we searched have very limited clinical trials and therefore it is hard to compare and understand their efficacy and side effects for longer clinical uses [35, 36]. Hence, we propose to increase the number of clinical trials because of these reasons.

The clinical trials of the plants listed in Table 4 are different from each other, that's why the evaluation of these studies was done within some rules. The most important of these rules is the evidence hierarchy, when the data contradict each other. Therefore, the results of the meta-analysis are strongest evidence, when there is any contradiction. However, in some cases, the results of the retrospective studies could be also very important, even though they represent weak evidence [62]. Meta-analysis and randomized controlled trials are at the top of the evidence pyramid, while the case reports and expert opinions are at the bottom of the evidence pyramid. The best evidence is quality, while considering these studies. The quality of evidence increases as it goes from bottom to top [63]. Randomization provides epidemiologically the highest quality data. When randomization is not appropriate for various reasons, researchers may be required to rely on non-randomized studies. In randomized studies, performing blind study is to prevent taking sides. In the single-blind studies, only researchers or patients are not aware of the drug, while both patients and researchers do not know which drug is given to which group in the double-blind studies. These studies are among the valuable studies in the evidence pyramid.

As the technique and technology in the field of medicine advance, research on the use of herbs in diseases may differ over the centuries. For example, Sambucus ebulus L. has been used for different ailments including: joint pains, cold, wounds, and infections. Nevertheless, recent evidence has revealed its potential for making attempts at treating cancer and metabolic disorders [64]. This review aimed to provide a comprehensive information of herbs regarding their traditional uses and modern findings which may contribute to the development of novel natural-based therapeutic agents.

Conclusions
Most of the uses of herbs studied in the clinical trials appear to be similar to their traditional uses. Many products prepared from these plants are sold in the market.
However, there are some plants on which their clinical uses differ from the traditional uses. As shown in Table 3, these are: *A. sativum, Borago officinalis, Calendula officinalis, Euphorbia peplus, Ficus carica, Foeniculum vulgare, Melissa officinalis, Myrtus communis, Rosmarinus officinalis and Urtica dioica*.

As evident from Table 4, wound healing is the investigated mostly issue in clinical studies with traditional uses and clinical trials.
### Table 4 Clinical trials of the traditional plants used for skin problems in Turkey

| Study          | Patient population | Inclusion and Exclusion criterias | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|----------------|--------------------|-----------------------------------|--------------------------|----------|----------|----------------------|------------|
| Alkanna tinctoria | N = 60             | Inclusion: Wounds after removal of the skin graft. Exclusion: Hypersensitivity reaction to the topical formulation, diabetes, renal failure, liver failure, malnourishment, cancer and hypoalbuminemia (serum albumin < 4 g/dl), as well as elderly (age > 60 years) and pregnant patients | RCT, SB, PBO-controlled Groups: A. tinctoria: dressing with its root extract ointment 20% PBO: standard dressing (dressing with standart ointments) Follow-up at 4 weeks | Primary: Wound healing Secondary: The percentage change in wound surface area, complete healing, adverse effects | Wound scores (Bates-Jensen wound assessment tool): A. tinctoria: Day 0: 25.07 ± 7.24 (p = 0.08) Day 14: 9.97 ± 1.30 (p = 0.001) Day 28: 9.03 ± 0.18 (p = 0.001) PBO: Day 0: 25.17 ± 7.42 (p = 0.08) Day 14: 20.63 ± 6.64 (p = 0.001) Day 28: 11.83 ± 2.77 (p = 0.001) Complete wound healing (Patients with Wound score < 10, n (%)) A. tinctoria: Day 14: 15 (50%) (p = 0.001) Day 28: 29 (96.66%) (p = 0.001) PBO: Day 14: 0 (0%) Day 28: 7 (23.3%) (p = 0.001) Statistically significant difference was found between the wound scores of treatment and placebo groups. | No side-effects were noted during the study | [35] |
| Allium cepa     | N = 90             | Inclusion: Surgical wounds at least 2.5 cm, Asians over 18 years age. Exclusion: Wound infections, taking agents that would affect wound healing, comorbidities such as diabetes, contractive skin disorders | RCT Groups: A. cepa extract 10% (Contractu-bex®)- 30 persons (twice daily) Silicone gel 10% (Kelo-cort®)- 30 persons (twice daily) No treatment group-30 persons Follow-up at 12 weeks | Primary: Objective scar assessment Secondary: Subjective scar assessment, subject- reported compliance, adverse effects | A. cepa/ Silicone gel/ No treatment Objective scar assessment (results) Vancouver Scar Scale: 3.8 ± 1.4/ 3.9 ± 1.1/5.4 ± 1.1 (first and second group difference p = 0.492 Not significant) Image Panel Scale: 5.2 ± 1.7/ 5.4 ± 1.1/ 6.2 ± 1.3 (first and second group difference p = 0.331 Not significant) Subjective scar assessment Body Image Scale: 16.8 ± 3.8/ 16.3 ± 2.3/14.9 ± 1.9 (first and second group difference p = 0.175 Not significant) Cosmetic Scale: 15.9 ± 3.6/ 15.7 ± 4.2/13.7 ± 3.0 (first and second group | Patient compliance with the gel: A. cepa/ Silicone gel Excellent: 20(67%), 21(70%) Good: 8(27%),8(27%) Poor: 1(3%), 2(7%) Adverse events with the gel Irritation: 2(7%), 1 (3%) Itching: 1(3%), 0 Erythema and Burning sense: 0 | [36] |
| Study                  | Patient population | Inclusion and Exclusion criterias | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|------------------------|--------------------|-----------------------------------|--------------------------|----------|----------|--------------------|------------|
| **Allium cepa** N = 24 | Inclusion: New surgical wounds at least 4 cm Exclusion:- | RCT, DB, split-scar Each scar was divided into two equal portions, and each half was assigned treatment with either onion extract gel or petrolatum. Each product was applied three times daily Treatment up to 8 weeks and evaluation up to 12 weeks | Outcomes: Scar healing | A. cepa extract/ Petrolatum | Week 2: Redness: 2.45 ± 0.50/ 2.50 ± 0.44 (p = 0.9414) Itchiness: 1.58 ± 0.53/ 1.09 ± 0.38 (p = 0.2841) Burning: 0.77 ± 0.34/ 0.85 ± 0.35 (p = 0.8483) Pain: 0.68 ± 0.29/ 0.68 ± 0.29 (p = 4259) Cosmetic appearance: Same changes 11(%46)– Better 5(21%)/ Better 8(33%)(p = 3654) Week 12: Redness: 0.29 ± 0.11/ 0.29 ± 0.13 (p = 0.9142) Itchiness: 0.86 ± 0.047/0.57 ± 0.027 (p = 0.4533) Burning: 0.043 ± 0.02/ 0.043 ± 0.02 (p = 1.0000) Pain: 0.043 ± 0.02/ 0.043 ± 0.02 (p = 1.0000) Cosmetic appearance: Same changes 12(%86)- Better 1(7%)/ Better 1(7%) Not significant difference was seen in any value for 12 weeks | No side-effects were noted during the study | [37] |
| **Allium sativum, H. perforatum, Calendula officinalis** N = 25 | Inclusion: Venous ulcers Exclusion: Ulceration greater than 10 cm2, clinical signs of infection | Non-RCT, Pilot Treatment: Herbadermal® (Dry water extract of Allii sativi bulbus (2.7% allicin), | Outcomes: Venous ulcers healing | Ulcer area and healing parameters: Persons: 1–5 / 6–10 / 11–15 / 16–20 / 21–25 Before and after the | No side-effects were noted during the study | [38] |
### Table 4 Clinical trials of the traditional plants used for skin problems in Turkey (Continued)

| Study | Patient population | Inclusion and Exclusion criterias | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|-------|--------------------|----------------------------------|--------------------------|----------|----------|----------------------|------------|
| thombophlebitis; hyperglycemia; kidney disease, or malignancy. | Dry ethanol extract of *Hyperici herba* (total flavonoid 3.1%; hypericin 0.1%), Oil extract of *Calendulae flos* (1:5; total flavonoids 0.02%) and vaseline | Ointment was applied topically 5 times a day over a period of 7 weeks. Follow-up at 7 weeks | study: | Pre-treatment: 4.23 / 7.54 / 7.22 / 6.32 / 6.98 Week 1: 3.80 / 7.45 / 7.0 / 6.14 / 6.9 Week 3: 3.12 / 6.91 / 6.3 / 5.75 / 5.6 Week 5: 2.76 / 5.76 / 5.8 / 4.0 / 4.1 Week 7: 0.0 (%100), 4.7 (%37.66), 5.2 (%31.03), 2.8 (%62.86), 1.8 (%76.12) Epithelialization: Average score/Improvement % Week 0: 7.43 /– Week 1: 4.56 /38.56 Week 3: 1.46 /80.26 Week 5: 0.46 /93.72 Week 7: 0.25 /99.10 Ulcer surroundings: Week 0: 7.23 /– Week 1: 5.10 / 29.49 Week 3: 3.33 / 53.91 Week 5: 2.93 / 59.44 Week 7: 2.13 / 70.50 Number of patients with isolated bacteria Week 0/1/3/5/7 *S.aureus*: 5 /– /5 /– /– *P.aeruginosa*: 5 /– /5 /– /– Especially, epithelialization results are significant. But, the method of the study is limited. | No side-effects were noted during the study | [39] |
| Borago officinalis | Inclusion: Children with atopic dermatitis | Exclusion: The patients with severe symptoms | RCT, DB, PBO- controlled Treatment: Undershirts coated with borage oil (including 498 mg of gamma linolenik asit per 100 g of cotton) PBO: Non-coated undershirts Follow-up at 2 weeks | Outcomes: Changes of clinical symptoms Changes of scores of the clinical symptoms Treatment group: Week 0: Itch: 1.44 ± 0.51 Erythema: 0.81 ± 0.83 Transepidermal water loss: 10 Week 2: Itch: 0.94 ± 0.57 (p = 0.033) Erythema: 0.31 ± 0.48 (p = 0.033) Transepidermal water loss: 7–7.5 (p = 0.0480) While itching and erythema revealed | | | |
Table 4 Clinical trials of the traditional plants used for skin problems in Turkey (Continued)

| Study | Patient population | Inclusion and exclusion criteria | Design and intervention | Outcomes | Efficacy | Safety/ tolerance | References |
|-------|--------------------|----------------------------------|--------------------------|----------|----------|------------------|------------|
| *Calendula officinalis* | N = 41 | Inclusion: Patients with diabetic foot ulcers, adequate glycemic control, neuropathic ulcers (0.5–45 cm²), age 18–90 years Exclusion: Active Charcot foot, Cellulitis, osteomyelitis, gangrene, or deep tissue infection, pregnant women, allergy, receiving systemic corticosteroids | Prospective, descriptive Treatment: Hydroglyco-lic 4% flowers extract of *C.officinalis* for twice daily Follow-up at 30 weeks | Ulcers healing: Ulcer area reduction and healing rate: Ulcer area (cm²): Baseline: 8.68 ± 8.55 Week 30: 0.57 ± 1.68 Healing rate (week 30): Complete healing: 32 (78%) The remaining 9 (22%) achieved an overall reduction in the wound area of 75%. Ulcer types: Baseline: Week 30 Wagner I: 34 (82.9%)- 9 (21.9%) Wagner II 7 (17.1%)- 0 (0.0%) Ulcer microbiology: Baseline: Week 30 Colonized diabetic foot ulcers: 26.8%-14.6% Infected diabetic foot ulcers: 48.8% 2.4% Ulcer duration (weeks): Median (range) Baseline: 65.0 Week 30: Complete healing was seen for 78% of Ulcers | No side-effects were noted during the study | [40] |
| Study | Patient population | Inclusion and Exclusion criterias | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|-------|-------------------|----------------------------------|-------------------------|----------|----------|-----------------------|------------|
| Calendula officinalis | N = 51 | Inclusion: Diagnosed with head and neck cancer and taken radiotherapy, aged over 18 years. Exclusion: Tumor wounds in the head and neck, previous history of radiotherapy in the same treatment field, allergy. | RCT, DB. Treatment: 4% Calendula oil, 1% vitamin A and liquid vaseline. Control: Essential fatty acid - sunflower oil, 1% vitamin A, 0.2% vitamin E and 5% caprylic acid. | Primary outcomes: Development of radiodermatitis. Radiation Therapy Oncology Group Acute Skin Toxicity Grades. | Development of radiodermatitis. 10th session of radiotherapy: Essential fatty acid (n = 27) - Calendula (n = 24). Grade 0: 24(88.89%)-22(91.67%). Grade 1: 3(11.11%)-2(8.33%). 35th session: Grade 0: 0(0%)-2(22.22%). Grade 1: 4(14.29%)-5(55.56%). Grade 2: 1(4.62%)-0(0%). Grade 3: 2(7.74%)-2(22.22%). Last session: Grade 0: 1(3.70%)-3(21.43%). Grade 1: 6(46.15%)-8(57.14%). Grade 2: 3(23.08%)-1(7.14%). Grade 3: 3(23.08%)-2(14.29%). 30 days after the treatment period: Grade 0: 9(90%)-11(91.67%). Grade 1: 0 (0%)-1(8.33%). Grade 2: 1(10%)-0(0%). Calendula showed better therapeutic response than the essential fatty acid, as the proportion of radiodermatitis Grade 2 in the essential fatty acid group is higher than Calendula group. | No side-effects were noted during the study. | [41] |
| Calendula officinalis | N = 254 | Inclusion: The women, 18 to 75 years of age, with a nonmetastatic breast adenocarcinoma treated by either lumpectomy or mastectomy with or without adjuvant postoperative chemotherapy or hormonal treatment. | Phase III, RCT. Treatment: Coifficinalis®(Pommade au Calendula par Digestion). Control: Trolamine. | Primary: Prevention of skin toxicity of Radiation Therapy Oncology Group grade 2 or higher. Secondary: Assessment of pain, allergy, dermatitis, patient satisfaction, the quantity of the Skin Toxicity in breast cancer patients treated with postoperative radiotherapy. Skin toxicity (grade): Calendula/ Trolamine Breast: 0–1: 78(79%)-75(71%). 2–3: 21(21%)- | No side-effects were noted during the study. | [42] |
Table 4 Clinical trials of the traditional plants used for skin problems in Turkey (Continued)

| Study | Patient population | Inclusion and Exclusion criterias | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|-------|---------------------|----------------------------------|-------------------------|----------|---------|----------------------|------------|
|       |                     |                                  |                         |          |         |                      | [43]       |
| Calendula | N = 50             | Inclusion: Skin ulcer caused by punch biopsy Exclusion: History of hypersensitivity to phenytoin, immune suppression (cancer, HIV), autoimmune disorders, malignancy, pregnancy. Exclusion:                         | RCT, DB Treatment: 5% Quince seed cream Control: 1% phenytoin cream All creams were used to twice a day for 2 weeks | Primary: Healing of ulcers Secondary: Adverse effects The Mean of Ulcer Size Before and After the Treatments: P. phenytoin/ C. oblonga Before: 0.525 ± 0.060/ 0.533 ± 0.090 (p = 0.740) Day 3: 0.306 ± 0.041/ 0.170 ± 0.109 (p = 0.001) Day 7: 0.161 ± 0.172/ 0.043 ± 0.029 (p = 0.003) Day 14 0.033 ± 0.026/ 0.004 ± 0.005 (p = 0.001) Complete healing percentage: Day 3: 0/0 Day 7: 0/%13.6 Day 14: %21.7/ %86.4 Complete healing rate and changes of Adverse effects Phenytoin/ C. oblonga: Burning: 26.1%/ 9.1% Pain: 13%/ 0% Itching: 8.7%/ 13.6% Contact dermatitis: 4.3%/ 0% No complications: 39.1%/ 77.3% |          |         |                      | [43]       |
| Study                  | Patient population | Inclusion and Exclusion criteria | Design and intervention | Outcomes                          | Efficacy                                      | Safety/ Tolerability | References |
|-----------------------|--------------------|----------------------------------|--------------------------|-----------------------------------|----------------------------------------------|----------------------|------------|
| Euphorbia peplus      | N = 36             | Inclusion: Patients with basal cell carcinoma, intraepidermal carcinoma or squamous cell carcinomas | Phase I/II Treatment: 100–300 uL of E. peplus sap once daily for 3 days | Outcomes: Treatment of Non-melanoma skin cancer | Ulcer size in the treatment group was seen statistically superior to the control group. | Number of lesions showing complete clinical response, partial clinical response and stable disease (5 at 1 month Basal cell carcinoma (no:28): 23(82%)/5(18%)/0 Intraepidermal carcinoma(16): 15(94%)/0/1(6%) Squamous cell carcinomas(4): 3(75%)/0/1(25%) Complete response at last follow-up: Basal cell carcinoma: 16(57%) Intraepidermal carcinoma: 12(75%) Squamous cell carcinoma: 2(50%) Biopsy histology (no: negative/no. tested) Basal cell carcinoma: 18/20 Intraepidermal carcinoma: 7/8 Squamous cell carcinoma: 1/2 Complete healing was seen for the most of the patients | No side-effects were noted during the study | [2]        |
| Ficus carica          | N = 59             | Inclusion: Children with atopic dermatitis Exclusion: Severe atopic dermatitis (Scoring atopic dermatitis index > 50), secondary skin infection, another skin disease, immunodeficiency disorder | RCT, DB, PBO Treatment: Fig fruit extract 8% (Melfi cream) Control: Hydrocortisone 1% Pbo: Base cream The patients were instructed to apply their allocated creams twice a day for two weeks. | Primary: Reduction of main symptoms (intensity and pruritus) Secondary: Complete healing, adverse effects Scoring atopic dermatitis Before/After Treatment: 33.84 ± 10.05/14.85 ± 8.83 (p < 0.0001) Control: 29.53 ± 13.58/16.73 ± 9.44 (p < 0.001) Pbo: 28.48 ± 10.34/34.30 ± 12.61 (Placebo results are failed) Intensity Treatment: 6.75 ± 2.81/3.06 ± 1.80 (p < 0.0001) Control: 6.28 ± 2.84/3.28 ± 1.77 (p < 0.001) Pbo: 5.60 ± 2.22/6.93 ± 2.89 (Placebo results are failed) | No side-effects were noted during the study | [44]       |
| Study | Patient population | Inclusion and Exclusion criterias | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|-------|--------------------|----------------------------------|-------------------------|----------|----------|----------------------|------------|
| Pruritus | Treatment: $5.31 \pm 2.70/1.93 \pm 1.91 \ (p < 0.0001)$ | Control: $3.50 \pm 2.76/2.35 \pm 1.98 \ (p < 0.004)$ | Pbo: $5.0 \pm 2.80/5.66 \pm 2.92 \$ | Treatment with fig extract had significant efficacy in terms of reducing the Scoring atopic dermatitis index, pruritus and intensity scores in comparison with Hydrocortisone 1.0% $(p < 0.05)$. | No side-effects were noted during the study | [45] |
| Foeniculum vulgare | $N = 38$ | Inclusion: Female patients with idiopathic hirsutism localized to the face | RCT, DB, PBO Treatment: *F. vulgare* (fennel) seed extract 1%, 2% Pbo: Vehicle cream The creams were applied twice daily for 12 weeks | Outcomes: Reduction of hair diameters in patients | Baseline characteristics of three study groups Average hair diameter Fennel 1%: 67.5 Fennel 2%: 59.9 Pbo: 53.8 The mean value of reduction of hair diameter Fennel 1%: 7.8% (SD = 3.7) Fennel 2%: 18.3% (SD = 8.3) Pbo: – 0.5% (SD = 2.1) The efficacy of treatment with the fennel extracts is more potent in comparison with the placebo. | No side-effects were noted during the study | [45] |
| Foeniculum vulgare | $N = 22$ | Inclusion: Patients with mild to moderate idiopathic hirsutism limited to face Exclusion: Severe hirsutism, increased serum androgen level. | RCT, DB, PBO Treatment: *F. vulgare* (Fennel) gel 3% Pbo: Vehicle cream Follow-up at 24 weeks | Primary: Changes in hair thickness Moderate: 20(9%)/12(60%) | Degree of hirsutism Treatment/PBO Mild:2(9%)/8(40%) Moderate: 20(9%)/12(60%) | No side-effects were noted during the study | [46] |
| Hypericum perforatum | $N = 21$ | Inclusion: Patients with subacute atopic | RCT, DB, PBO Treatment: *H.* | Primary: The clinical intensity of skin The half-side comparison of skin In total, 4 adverse events were | In total, 4 adverse events were | [47] |
| Study | Patient population | Inclusion and Exclusion criterias | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|-------|--------------------|-----------------------------------|-------------------------|----------|----------|---------------------|------------|
| dermatitis (Scoring atopic dermatitis index< 80) Exclusion: Infectious disease, Severe underlying clinical disease | | perforatum extract cream (20–25:1; hyperforin content of 1.5%) PBO: Vehicle cream The patients were treated twice daily over a period of four weeks | | the skin lesions Secondary: Bacterial colonisation of skin lesions, skin tolerance and cosmetic acceptability of the study medications | lesion intensities (Scoring atopic dermatitis index) Change from baseline: Mean ± SD/ Median [min; max]/ 95% CI/ p-value Day 7: Treatment: −3.0 ± 3.1/ −3.0 [−10.0; 5.0] / [−5.0; −2.0] / (p = 0.002) Placebo: −0.6 ± 1.2/ −0.5 [−2.0; 2.0]/ [−2.0; 0.0]/ (p = 0.002) Day 14: Treatment: −4.7 ± 3.3/ −6.0 [−10.0; 2.0]/ [−7.0; 3.0]/ (p = 0.016) Placebo: −2.1 ± 3.0/ −2.0 [−10.0; 4.0]/ [−4.0; 0.0]/ (p = 0.016) Day 28: Treatment: −5.4 ± 4.9/ −6.5 [−12.0; 5.0]/ [−9.0; −4.0]/ (p = 0.022) Placebo: −2.3 ± 3.3/ −2.5 [−8.0; 5.0]/ [−4.0; −1.0]/ (p = 0.022) Number of CFUs of bacteria in general and of Staphylococcus aureus in particular | | | |
| | N = 134 | | | | recorded in 3 patients. None of the adverse events was classified as serious. In all cases, there was an acute episode of atopic dermatitis leading to withdrawal from the study. One patient additionally developed contact eczema; in this instance a relationship with the study medication (hypericum-free vehicle) was considered probable. | | | |
| Achillea millefolium, H. perforatum | Inclusion: Primiparous women with episiotomy wounds, being nulliparous; gestational age of RCT, PBO, DB Treatment groups: 1- H. perforatum ointment (Group 1) 2- A. millefolium ointment (Group 2) | | | Outcomes: Healing of wounds | Group 1 [Min/Max/ Median/IQR]- Group 2 [Min/Max/Median/ IQR]- Placebo [Min/ Max/Median/ IQR]- No intervention | | [48] |
| Study | Patient population | Inclusion and Exclusion criterias | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|-------|--------------------|----------------------------------|--------------------------|----------|----------|----------------------|------------|
|       | 37–42 weeks; having a single fetus; no use of particular medications | Exclusion: mismatch between the fetus head and the mother’s pelvis in pelvic examination; disorder in the labor progress; manual placenta removal; third and fourth degree perineal rupture | 3- Placebo ointments (PBO) 4- Non-inter- vention (NI) The patients were treated twice a day for 10 days | (Min/Max/Median/IQR) Pain level 2th Day Group 1: 3/10/9/2.5 - Group 2: 6/10/9/2 - PBO: 3/10/9/2 - NI: 6/10/9/2 (p = 0.226) 7th Day Group 1: 0/7/4/2.5 - Group 2: 3/8/6/2 - PBO: 1/9/6/5 - NI: 4/9/7/1 (p < 0.001) 10th Day Group 1: 0/5/2/2.5 - Group 2: 0/6/4/2 - PBO: 0/8/5.5/1.2 - NI: 2/8/6/2 (p < 0.001) 14th Day Group 1: 0/3/0/1 - Group 2: 0/5/0/2 - PBO: 0/7/3/4.25 - NI: 0/7/4/3 (p < 0.001) Redness 7th Day Group 1: 0/8/3/5 - Group 2: 0/15/5/6 - PBO: 0/15/7/3.5 - NI: 5/15/8/4 (p < 0.001) 10th Day Group 1: 0/5/0/0 - Group 2: 0/8/0/2.5 - PBO: 0/12/4/5 - NI: 0/12/5/2 (p < 0.001) 14th Day Group 1: 0/0/0/0 - Group 2: 0/5/0/0 - PBO: 0/10/0/0.5 - NI: 0/10/0/4 (p < 0.001) Ecchymosis 7th Day Group 1: 0/3/0/0 - Group 2: 0/3/0 - PBO: 0/6/0/5 - NI: 0/7/0/5 (p < 0.001) 10th Day Group 1: 0/0/0/0 - Group 2: 0/0/0 - PBO: 0/4/0/0 - NI: 0/4/0/0 (p < 0.041) Edema 7th Day Group 1: 0/5/0/4.5 - Group 2: 0/10/0/5 - PBO: 0/15/5/5.5 - NI: 0/15/5/3 (p < 0.001) 10th Day Group 1: 0/0/0/0 - Group 2: 0/5/0/0 - PBO: 0/8/0/1 - NI: 0/10/0/5 (p < 0.001) 14th Day Group 1: 0/0/0/0 - Group 2: 0/0/0 - PBO: 0/4/0/0 - NI: 0/5/0/0 (p = 0.322) | Alan et al. Clinical Phytoscience (2021) 7:79 | Page 14 of 29 |
| Study | Patient population | Inclusion and Exclusion criteria | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|-------|---------------------|---------------------------------|-------------------------|----------|----------|---------------------|------------|
| H. perforatum, Calendula arvensis | N = 24 | Inclusion: Surgical wounds from childbirth with caesarean section. Exclusion: | Non-RCT | Treatment: A mixture of oily extracts of H. perforatum 70% and C. arvensis 30% Control: Wheat germ oil (320:1000) The two groups were treated twice daily for 16 consecutive days. | Outcomes: Healing of surgical wounds, Surface Perimeter Area assessment | Area of surgical wounds before and after treatment with the Hypericum–Calendula oily extract (treated group) Surface Perimeter Area (before-after)/% wound reduction Mean: 13.58 ± 2.71 – 8.16 ± 1.40 (%37.6 ± 9.9) Extension of the wound before and after treatment with wheat germ oil (control group) Surface Perimeter Area (before-after)/% wound reduction Mean: 15.75 ± 2.13 / 12.66 ± 2.49 (%15.83 ± 4.64) The Hypericum–Calendula mixture was found superior to the control. | No side-effects were noted during the study [49] |
| Study          | Patient population | Inclusion and Exclusion criterias | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|---------------|--------------------|-----------------------------------|--------------------------|----------|----------|--------------------|------------|
| *H. perforatum* | N = 10             | Inclusion: Symmetrical plaque-type psoriasis Exclusion:- | Single-blind, PBO, Pilot study Treatment: *H. perforatum* (5% wt/wt), vaseline (84% wt/wt), propylene glycol (10% wt/wt) and avicel (1% wt/wt) PBO: Vehicle cream - The hypericum ointment was applied to one side of each patient's body and the vehicle to the opposite side twice daily for 4 weeks | Outcomes: Healing of erythema | Mean erythema scores, scaling scores, and thickness scores Before/ After Treatment: Erythema: 2.6 (2.6 ± 0.5)/ 1.1 (1.1 ± 0.74)* Scaling: 2.5 (2.5 ± 0.85)/ 0.7 (0.7 ± 0.48)* Thickness: 2.4 (2.4 ± 0.52)/ 1.1 (1.1 ± 0.74)* PBO: Erythema: 2.6 (2.6 ± 0.7)/ 1.9 (1.9 ± 0.74)* Scaling: 2.4 (2.4 ± 0.52)/ 2.1 (2.1 ± 0.57)* Thickness: 2.1 (2.1 ± 7.4)/ 1.8 (1.8 ± 0.42)* *A statistically significant difference was found between the scores after treatment in placebo and formulated active ointment (P = 0.01, P = 0.004, P = 0.04). But the method of study is limited. | No side-effects were noted during the study | [50] |
| *H. perforatum* | N = 125            | Inclusion: Women with first surgical childbirth, age range 17–35 years Exclusion: Scars from prior abdominal surgery, history of medical and obstetrical problems | RCT, DB Treatment: Oily extract of *H. perforatum* PBO: Vehicle ointment Control: No intervention The two groups were treated three times daily for 16 consecutive days | Outcomes: Healing of wounds Assesment of the Wound Healing by the REEDA Scale on the 10th Day Postpartum Treatment (n = 47)/ Placebo (n = 42)/ Control (n = 34) Redness: 0.11(0.31)/ 0.36(0.49)/ 0.35(0.49) [χ² = 9.56, p < 0.008] Edema: 0.06(0.25)/ 0.05(0.21)/ 0.21(0.41) [χ² = 6.53, p < 0.04] Ecchymosis: 0.02(0.14)/0.00 (0.00)/ 0.00 (0.00) [χ² = 1.66, p = 0.44] Discharge: 0.00(0.00)/ 0.20(0.59)/ 0.21(0.54) [χ² = 7.22, p < 0.03] Approximation: 0.00 (0.00)/ 0.16(0.37)/ 0.03(0.17) [χ² = 10.45, p < 0.005] REEDA: 0.19(0.50)/ 0.75(1.08)/ 0.79(1.17) | No side-effects were noted during the study | [51] |
Table 4 Clinical trials of the traditional plants used for skin problems in Turkey (Continued)

| Study          | Patient population | Inclusion and Exclusion criterias | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|----------------|--------------------|----------------------------------|--------------------------|----------|----------|----------------------|------------|
| Lavandula stoechas | N = 120            | Inclusion: Primiparous women underwent episiotomy Exclusion: Allergy | RCT Treatment: Essential Lavender oil Control: Povidone-iodine The two groups were treated twice daily for 10 consecutive days. | Outcomes: Healing of episiotomy | Comparison of episiotomy healing evaluation in treatment and control groups Control/ Treatment Pain: No pain: 17 (28.3%)/25 (41.7%) Moderate: 25 (41.7%)/27 (45%) Severe: 18 (30%)/8 (13.3%) [p = 0.063] Edema: No edema: 36 (60%)/30 (50%) 1–2 (cm): 19 (15%)/16 (26.7%) 2+: 7 (1.7%)/0 (0%) [p = 0.320] Leaved suture: No: 27 (45%)/24 (40%) 1–3: 18 (30%)/16 (26.7%) | No side-effects were noted during the study | [52] |

\[\chi^2 = 10.51, p < 0.005\]
Assessment of the Hypertrophic Scar by the Vancouver scar scale on the 40th Day Postpartum Treatment (n = 44)/Placebo (n = 40)/Control (n = 32) Pigmentation: 1.91 (0.05)/2.58 (0.68)/2.62 (0.71) \[\chi^2 = 15.72, p < 0.00001\] Height: 0.41 (0.50)/0.73 (0.55)/0.84 (0.37) \[\chi^2 = 15.21, p < 0.00001\] Pliability: 0.98 (0.63)/1.60 (0.59)/1.84 (0.63) \[\chi^2 = 30.03, p < 0.00001\] Vascularity: 0.02 (0.15)/0.15 (0.36)/0.16 (0.37) \[\chi^2 = 4.95, p = 0.08\] Vancouver: 3.32 (1.54)/5.03 (1.29)/5.50 (0.92) \[\chi^2 = 43.23, p < 0.00001\] There were significant differences in wound healing and scar formation between treatment with placebo and control groups.
### Table 4 Clinical trials of the traditional plants used for skin problems in Turkey (Continued)

| Study | Patient population | Inclusion and Exclusion criteria | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|-------|--------------------|----------------------------------|--------------------------|----------|----------|---------------------|------------|
| Melissa officinalis | N = 120 | Inclusion: History of recurrent herpes labialis (at least 4 episodes per year), experiences in noticing the typical prodromes (itching, tingling, burning, tautness) Exclusion: - | RCT, DB, PBO Treatment: 1% Lo-701 - dried extract from lemon balm leaves (70:1) PBO: Vehicle cream The two groups were treated four times daily for 5 days | Outcomes: Healing of Herpes labialis Daily score of herpetic symptoms on day 2 of therapy Treatment: 4.03 ± 0.33 PBO: 4.94 ± 0.40 ($p = 0.042$) Total score of symptoms in both treatment groups over 5 days Treatment: 13.3 ± 0.96 PBO: 14.9 ± 1.24 ($p = 0.16$) Significant difference was seen on day 2 of therapy but the difference on day 5 wasn’t statistically significant. | No side-effects were noted during the study | [53] |
| Myrtus communis (myrtle) | N = 20 | Inclusion: Women with acne skin Exclusion: Atopy, chronic skin disease, having another acne treatment, taken a medicine which may affect the hormonal system | Non-randomized controlled trial Treatment: Foam cleanser, toner, emulsion, and cream pack including myrtle essential oil Control: Foam cleanser, toner, emulsion, and cream pack without myrtle The two groups were treated twice daily for 6 weeks | Outcomes: Healing of acne skin The comparison of erythema in groups weekly Treatment/ Control Week 0: 392.5 ± 62.5/ 378.3 ± 47.9 Week 3: 379.5 ± 57.9/ 387.5 ± 68.3 Week 6: 365 ± 48.4/ 386 ± 68.2 ($p = 0.083$) The comparison of sebum in groups weekly Week 0: 7.6 ± 2.7/ 8.7 ± 5.4 Week 3: 6.7 ± 2.4/ | No side-effects were noted during the study | [54] |

4–6: 15(25%)/ 20(33.3%) ($p = 0.62$) Redness: No: 13(21.7%)/ 31(51.7%) 1–3: 8(13.3%)/ 6(10%) 4–7: 11(18.3%)/ (15 25%) 7>: 28(46.7%)/ 8(13.3%) ($p = 0.001$) Dehiscence: Yes: 26(43.3%)/ 19(31.7%) No: 34(56.7%)/ 41(68.3%) ($p = 0.129$) There was no significant difference between two groups in surgery site complications. However, redness in the lavender group was significantly less than controls ($p < 0.001$).
Table 4: Clinical trials of the traditional plants used for skin problems in Turkey (Continued)

| Study | Patient population | Inclusion and Exclusion criterias | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|-------|--------------------|----------------------------------|-------------------------|----------|----------|---------------------|------------|
|       | 9.5 ± 5.4          | Week 6: 5.2 ± 2.7/ 9.2 ± 4.3 \(p = 0.033\) The comparison of desquamation in groups weekly Week 0: 245.2 ± 95.2/ 232.5 ± 101.5 Week 3: 241.9 ± 97.8/ 252.4 ± 97.5 Week 6: 146.3 ± 75.4/ 268.1 ± 96.1 \(p = 0.000\) The comparison of skin microorganism in groups weekly Week 0: 8343.9 ± 3486.6/ 7883.3 ± 2192.8 Week 3: 6436.2 ± 2710.4/ 7555.7 ± 2252.9 Week 6: 5009.4 ± 1863.3/ 7548.1 ± 2426 \(p = 0.009\) The comparison in weekly average of outstanding pores, large pores, and blackheads Myrtle (weeks 0:3:6)/ Control (weeks 0, 3, 6) Outstanding pores: 1271.9 ± 677.3: 1080.8 ± 586.7: 907.5 ± 484.6/ 1127.7 ± 905.9: 1132.5 ± 799.9: 1146.9 ± 853.8 \(p = 0.000\) Large pores: 38.8 ± 46.4: 35.1 ± 44.5: 34.5 ± 43.4/ 30.9 ± 54: 31.2 ± 53.5: 31.9 ± 54 \(p = 0.005\) Blackheads: 649.2 ± 468.2: 508.5 ± 342.4/ 287.2 ± 229.8/ 569.5 ± 630.1: 569.5 ± 630.1: 619.1 ± 647.1 \(p = 0.000\) The comparison in the group Korean acne grading scale (0,1,2,3,4): (Mean ± SD) Treatment/ Control Week 0: 1.8 ± 1.0/ 1.6 ± 0.8 Week 6: 0.9 ± 0.9/ 1.5 ± 0.7 \(p = 0.006\) Statistically significant differences were
Table 4 Clinical trials of the traditional plants used for skin problems in Turkey (Continued)

| Study | Patient population | Inclusion and Exclusion criterias | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|-------|--------------------|-----------------------------------|--------------------------|----------|----------|---------------------|------------|
| Olea europaea | N = 34 | Inclusion: Patients with diabetic foot ulcer (grade 1,2), age of 30–65 years, body mass index of 18 to 35 | RCT, DB Control: Olive oil Treatment: Olive oil | Outcomes: Healing of diabetic foot ulcer | Comparison of ulcer parameters and total ulcer status scores at the baseline and during follow-up visits in each group | No side-effects were noted during the study | [55] |

Treatment/ Control Degree:
Baseline: 69.0 ± 11.83 / 61.0 ± 17.54 (p = 0.154)
After 1 week: 79.33 ± 10.15 / 69.33 ± 17.30 (p = 0.064)
After 2 weeks: 87.33 ± 9.79 / 74.33 ± 17.20 (p = 0.017)
After 3 weeks: 92.33 ± 9.79 / 80.0 ± 16.47 (p = 0.019)
After 4 weeks: 96.66 ± 6.17 / 82.66 ± 15.56 (p = 0.03)

Color:
Baseline: 66.0 ± 9.10 / 65.33 ± 12.45 (p = 0.868)
After 1 week: 84.0 ± 9.85 / 69.0 ± 11.68 (p = 0.001)
After 2 weeks: 90.0 ± 10.1 / 78.66 ± 14.57 (p = 0.019)
After 3 weeks: 94.66 ± 6.11 / 83.00 ± 13.33 (p = 0.005)
After 4 weeks: 97.33 ± 4.57 / 86.66 ± 12.34 (p = 0.04)

Surrounding tissues:
Baseline: 67.0 ± 15.32 / 69.0 ± 11.68 (p = 0.691)
After 1 week: 81.33 ± 12.31 / 73.33 ± 8.16 (p = 0.045)
After 2 weeks: 90.33 ± 9.72 / 79.33 ± 12.22 (p = 0.011)
After 3 weeks: 94.66 ± 6.11 / 83.00 ± 13.33 (p = 0.005)
After 4 weeks: 97.33 ± 4.57 / 86.66 ± 12.34 (p = 0.04)
### Table 4 Clinical trials of the traditional plants used for skin problems in Turkey (Continued)

| Study | Patient population | Inclusion and Exclusion criterias | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|-------|--------------------|----------------------------------|--------------------------|----------|----------|----------------------|------------|
| 97.33 ± 4.57/ 83.0 ± 13.33 (p < 0.001) Drainages Baseline: 86.0 ± 14.54/ 84.0 ± 16.81 (p = 0.730) After 1 week: 93.33 ± 9.75/ 87.33 ± 15.33 (p = 0.212) After 2 weeks: 97.33 ± 7.03/ 92.66 ± 13.34 (p = 0.241) After 3 weeks: 98.86 ± 5.16/ 94.00 ± 10.55 (p = 0.135) After 4 weeks: 100.00 ± 0.00/ 96.00 ± 8.28 (p = 0.072) Total ulcer status Baseline: 288.00 ± 40.52/ 277.33 ± 35.55 (p = 0.450) After 1 week: 342.00 ± 33.63/ 301.67 ± 35.89 (p = 0.004) After 2 weeks: 365.00 ± 29.82/ 325.00 ± 43.91 (p = 0.007) After 3 weeks: 373.67 ± 37.48 / 43.00 ± 26.20 (p = 0.056) After 4 weeks: 391.33 ± 15.05/ 348.00 ± 43.08 (p = 0.001) At the end of the study: Complete healing: 73.33%/ 13.3% (p = 0.003) Partial healing: 26.7%/ 73.3% Lack of healing: 0%/ 13.3% Statistically significant differences were seen between the groups for the rate of complete ulcer healing at the end of study. Only, in terms of the results of ulcer drainages were not seen differences between the groups. | Olea europaea, Helianthus N = 19 Inclusion: Volunteers with and without a history of atopic RCT, SB, Forearm-controlled, cohort study Outcomes: Effect of Olive and Sunflower Seed Cohort 1(7 volunteers with a self-reported | Olive oil applied twice daily for 4 weeks (less than a | 56 |
| Study Population | Inclusion and Exclusion criteria | Design and Intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|------------------|---------------------------------|------------------------|----------|----------|---------------------|------------|
| annuus (Sunflower) | dermatitis <br> Exclusion: Volunteers who were pregnant, breastfeeding, or using prescription immunomodulatory medication in the last 6 months | Group 1: Olive oil (olive oil to the designated one forearm and opposite forearm acted as an untreated control) Group 2: Sunflower seed oil and olive oil (olive oil to one forearm and Sunflower seed oil to the other forearm) The two groups were treated twice daily for 5 weeks | Oil on the Adult Skin Barrier <br> previous history of atopic dermatitis (no symptoms for 6 months) | Cohort 2 (12 volunteers, 6 with no history of skin disease and 6 with a self-reported previous history of atopic dermatitis (no symptoms for 6 months) Biophysical properties of test sites before and after 4 weeks of treatment Sunflower seed oil (grouped/healthy/atopic dermatitis); Olive oil (grouped/healthy/atopic dermatitis) | Hydration (capacitance): <br> Sunflower: 115 ± 5.8 (p = 0.04) / 112 ± 9.7 (p = 0.39) / 118 ± 7.1 (p = 0.045); Olive: 110 ± 4.7 (p = 0.07) / 112 ± 6.1 (p = 0.15) / 109 ± 7.8 (p = 0.33) <br> Skin surface-pH Difference(%): <br> Sunflower: 0.01 ± 0.09 (p = 0.89) / 0.26 ± 0.08 (p = 0.02) / -0.23 ± 0.09 (p = 0.06); Olive: -0.01 ± 0.09 (p = 0.88) / 0.06 ± 0.13 (p = 0.66) / -0.09 ± 0.12 (p = 0.51) <br> Erythema Difference(%): <br> Sunflower: 100 ± 6.2 (p = 0.76) / 98 ± 10.7 (p = 0.07) / 103 ± 7.3 (p = 0.70); Olive: 114 ± 8.1 (p = 0.08) / 116 ± 10.5 (p = 0.17) / 112 ± 13.3 (p = 0.38) | In contrast to sunflower seed oil, topical treatment with olive oil can damage the skin barrier for patients with atopic dermatitis. Sunflower seed oil, when used in the same way, preserved stratum corneum integrity, caused a significant reduction in stratum corneum integrity and thickness, failed to impart a significant effect on stratum corneum hydration, and induced mild erythema in volunteers with and without a history of atopic dermatitis. | Alan et al. Clinical Phytoscience (2021) 7:79 |
### Table 4: Clinical trials of the traditional plants used for skin problems in Turkey (Continued)

| Study | Patient population | Inclusion and Exclusion criteria | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|-------|-------------------|---------------------------------|--------------------------|----------|----------|----------------------|------------|
| **Pistacia terebinthus** | N = 15 | Inclusion: Metastatic colorectal patients who developed skin toxicity while receiving first-line cetuximab in combination with chemotherapy | Non-randomized Treatment: P. terebinthus soap The group was treated twice daily for 1 week | Outcomes: Healing of skin toxicity | Did not cause erythema, and improved skin hydration by 12% to 18% in the same volunteers. | No side-effects were noted during the study | [57] |
| **Rosmarinus officinalis, Calendula officinalis** | N = 20 | Inclusion: Volunteers with healthy skin Exclusion: Severe internal diseases, pregnancy, lactation, and uncertain contraception, dermatological diseases, immunosuppressive therapy | RCT, PBO, SB Treatment groups: 1-Rosemary extract dyed 5% 2-Rosemary extract undyed 5% 3-Marigold extract dyed 5% 4-Marigold extract undyed 5% 5-Faradiol myristic acid | Outcomes: Protective effects in healthy volunteers with experiemntally induced Sodium-Lauryl-Sulfate Irritant contact dermatitis | Values of the visual score at days 1, 2, 3 and 5 Rosemary-undayed: 0/0.25/0.56/0.69 *** Cortisone: 0/0.44/0.69/0.69 *** Rosemary-dyed: 0/0.38/0.7/0.81 *** Marigold-dyed: 0/0.38/0.75/0.81 *** | No side-effects were noted during the study | [58] |
Table 4 Clinical trials of the traditional plants used for skin problems in Turkey (Continued)

| Study | Patient population | Inclusion and Exclusion criterias | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|-------|-------------------|-----------------------------------|--------------------------|----------|----------|----------------------|------------|
|       | ester 5%          | Inclusion: Patients RCT, Nonblinded | Ten minutes after application of the irritant, 9 test areas received treatment (parallel treatment). |          |          |          |             |
|       | 6-Faradiol palmitic acid ester 5% |                               |                          |          |          |          |             |
|       | 7-Faradiol ester-enriched fraction 5% |                               |                          |          |          |          |             |
|       | 8-Hydrocortisone 0.25% |                               |                          |          |          |          |             |
|       | 9-Base cream DAC (Deutscher Arzneimittel-Codex) |                               |                          |          |          |          |             |
|       | Marigold-undyed: 0/0.38/0.75/0.88 ** |                               |                          |          |          |          |             |
|       | FDE-enriched: 0/0.44/0.56/0.88 ** FD palmitic acid: 0/0.5/0.75/0.94 ** FD myristic acid: 0/0.5/0.81/1.31 ** DAC (vehicle): 0/0.56/0.69/1.06 ** Control (untreated): 0/0.88/1.44/1.75 |
|       | Marigold-undyed: 3.07/5.9/7.19 ** |                               |                          |          |          |          |             |
|       | FDE-enriched: 4.07/6.73/1.23 ** Cortisone: 3.79/6.17/1.73 *** Rosemary-dyed: 4.40/7.63/2.01 *** Marigold-dyed: 4.14/5.9/2.11 *** FD palmitic acid: 4.30/6.34/2.17 ** FD myristic acid: 3.88/6.61/2.31 ** Rosemary-undyed: 4.61/6.22/2.43 *** DAC (vehicle): 3.44/6.34/2.58 ** Control (untreated): 5.07/7.30/3.37 |
|       | Values of the Chromametry at days 2, 3 and 5 Marigold-undyed: 7.48/11.68/17.13 ** Rosemary-undyed: 6.05/10.76/17.54 ** Marigold-dyed: 7.29/12.53/18.55 ** Cortisone: 7.33/12.44/19.42 ** FDE-enriched: 6.40/11.53/19.58 ** FD palmitic acid: 6.94/11.99/21.18 Marigold-undyed: 7.79/14.49/22.02 ** FD myristic acid: 7.68/14.72/22.60 ** DAC (vehicle): 6.33/14.11/20.60 ** Control (untreated): 10.86/20.89/31.58 |
|       | Values of the Tewametry at days 2, 3 and 5 Marigold-undyed: 7.29/12.53/18.55 ** Rosemary-undyed: 6.05/10.76/17.54 ** Marigold-dyed: 7.29/12.53/18.55 ** Cortisone: 7.33/12.44/19.42 ** FDE-enriched: 6.40/11.53/19.58 ** FD palmitic acid: 6.94/11.99/21.18 Marigold-undyed: 7.79/14.49/22.02 ** FD myristic acid: 7.68/14.72/22.60 ** DAC (vehicle): 6.33/14.11/20.60 ** Control (untreated): 10.86/20.89/31.58 |
|       | Values of the Chromametry at days 2, 3 and 5 Marigold-undyed: 7.48/11.68/17.13 ** Rosemary-undyed: 6.05/10.76/17.54 ** Marigold-dyed: 7.29/12.53/18.55 ** Cortisone: 7.33/12.44/19.42 ** FDE-enriched: 6.40/11.53/19.58 ** FD palmitic acid: 6.94/11.99/21.18 Marigold-undyed: 7.79/14.49/22.02 ** FD myristic acid: 7.68/14.72/22.60 ** DAC (vehicle): 6.33/14.11/20.60 ** Control (untreated): 10.86/20.89/31.58 |

Vitis vinifera, N = 49 Inclusion: Patients RCT, Nonblinded Outcomes: Success rate of No side-effects were [59]
| Study | Patient population | Inclusion and Exclusion criteria | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|-------|---------------------|----------------------------------|-------------------------|----------|----------|---------------------|------------|
| Urtica dioica, Glycyrrhiza glabra, Alpinia officinarum, Thymus vulgaris | with anterior epistaxis Exclusion: Pregnant, epistaxis after the nasal operation, systemic disease, posterior epistaxis | Treatment: Ankaferd Blood stopper® (V. vinifera (0.08 mg/ml), U. dioica (0.06 mg/ml), G. glabra (0.07 mg/ml), A. officinarum (0.07 mg/ml), T. vulgaris (0.05 mg/ml)) Control: Phenylephrine Ankaferd blood stopper and phenylephrine tampons were applied when bleeding times. | Hemostatic efficacy | Ankaferd blood stopper and phenylephrine applications (Number of applications and success rates): 1: Treatment: 15 (62.5%), Control: 7 (28%) 2: Treatment: 4 (16.7%), Control: 9 (36.0%) No: Treatment: 5 (20.8), Control: 9 (36.0) (p < 0.05) Success rate of ankaferd blood stopper and phenylephrine compared against bleeding intensity (Bleeding intensity (1, 2, 3): group (application numbers) and success rates): 1: Treatment (1): 5 (100%), Treatment (2): 0 (0%), Treatment (unsu): 0 (0%), Control (1): 6 (85.7%), Control (2): 1 (14.3%), Control (unsu): 0 (0%) 2: Treatment (1): 5 (100%), Treatment (2): 0 (0%), Treatment (unsu): 0 (0%), Control (1): 1 (12.5%), Control (2): 6 (75%), Control (unsu): 1 (12.5%) 3: Treatment (1): 5 (35.7%), Treatment (2): 4 (28.6%), Treatment (No): 5 (35.7%), Control (1): 0 (0%), Control (2): 2 (20%), Control (unsu): 8 (80%) Treatment (unsu) and Control (unsu) values indicated unsuccessful rates. Ankaferd blood stopper was seen more effective than phenylephrine at control of anterior epistaxis (79.2 vs. 64%, p < 0.05). | noted during the study |
| Vitis vinifera | N = 47 | Inclusion: Pediatric patients undergoing | Outcomes: Blood loss, surgical time | Assessment of hemostasis time, No side-effects were noted during the study | [60] |
herbs. Because, skin wounds, either acute or chronic, might affect the quality of patients’ life significantly. Especially, chronic wounds might be progressive and resistant to treatments. These wounds become chronic because of a number of underlying conditions such as diabetes, vascular disease, and neuropathy [65–67]. Herbs studied clinically for general wound healing are: **Alkanna tinctoria, Allium cepa, H. perforatum, Achillea millefolium/H. perforatum** and **H. perforatum/Calendula arvensis**. Some studies have been also made in specific areas, these are: for episiotomy or caesarean section wounds with **Lavandula stoechas, Achillea millefolium/H. perforatum** and **H. perforatum/Calendula arvensis** combinations; for undergoing transradial catheterization and tonsillectomy with **Vitis vinifera/Urtica dioica/Glycyrrhiza glabra, Alpinia officinarum, Thymus vulgaris** for skin ulcer caused by punch biopsy with **Cydonia oblonga**.

Oncology is another important area where clinical studies with herbs have been carried out frequently. Although there is not much direct use of herbs in cancer treatment, they have been generally tried for the side effects of cancer treatment. However, an example of a clinical study can be given as follows, even if it is not used for this purpose in Turkey: **Euphorbia peplus** was tried directly for basal cell carcinoma, intraepidermal carcinoma or squamous cell carcinoma in Phase I/II clinical study [2]. Some herbs, such as the use of

---

**Table 4 Clinical trials of the traditional plants used for skin problems in Turkey (Continued)**

| Study | Patient population | Inclusion and Exclusion criterias | Design and intervention | Outcomes | Efficacy | Safety/ Tolerability | References |
|-------|--------------------|-----------------------------------|--------------------------|----------|---------|----------------------|------------|
| **Vitis vinifera, Urtica dioica, Glycyrrhiza glabra, Alpinia officinarum, Thymus vulgaris** | Inclusion: Patients undergoing transradial catheterization Exclusion: Sheath diameter different form 6F, age < 18 years, abnormal Barbeau’s test before puncture. | RCT, PBO Groups: 1 - Ankaferd Blood stopper® 2 - Conventional sterile Gauze 3 - TR band | Primary: Hemostatic efficacy Secondary: Radial artery occlusion | Treatment/Conventional sterile gauze/ TR band Radial artery occlusion at the end of hemostasis: 0(0)/1(0.49)/1(0.48) (p = 0.36) Radial artery occlusion at 24 h follow-up: 0(0)/1(0.49)/1(0.48) (p = 0.63) Radial artery occlusion at 30-day follow-up: 0(0)/0(0)/0(0) (p = 1.00) Hematoma: 4(1.98)/3(1.47)/2(0.97) (p = 0.70) Bleeding after device removal: 19(9.40)/55(26.96)/56(27.31) (p < 0.001) Statistically significant difference was found for the bleeding results. | No side-effects were noted during the study | [61] |
Calendula officinalis for radiotherapy or lumpectomy or mastectomy wounds, have also been tried to prevent skin problems that may develop due to cancer treatment [41, 42]. Another example, Pistacia terebinthus was tried in metastatic colorectal patients who developed skin toxicity while receiving first-line cetuximab in combination with chemotherapy [57].

Other skin diseases and plants that have been studied clinically are as follows: for atopic dermatitis: Borago officinalis, Ficus carica and H. perforatum, for diabetic foot ulcers adequate glycemic control, neuropathic ulcers: Calendula officinalis and Olea europaea; for epithelialization in venous ulcers: A. sativum/H. perforatum/Calendula officinalis combinations, for protective effects: Rosmarinus officinalis, Calendula officinalis or protection mild erythema Olea europaea/Helianthus annuus, for anterior epistaxis: Vitis vinifera/Urtica dioica/Glycyrrhiza glabra/Alpinia officinarum/ Thymus vulgaris, for idiopathic hirsutism localized to the face: Foeniculum vulgare, for symmetrical plaque-type psoriasis: H. perforatum, for acne: M. communis, for recurrent herpes labialis: M. officinalis. In addition, most of these herbs have been found to be statistically effective in their studies as shown in Table 4.

As a result, ethnobotanical studies could have an important role in the discovery of new drugs. Turkish traditional herbs learned from these studies have been used for various diseases locally, but more preclinical and clinical studies are needed to prove the clinical efficacy of these herbs and their compounds.

Abbreviations
DB: Double blind; NI: Non-intervention; PBO: Placebo; RCT: Randomized controlled trial; SB: Single blind

Acknowledgements
Not applicable.

Authors’ contributions
This work was carried out in collaboration between all authors. Authors EA, AYU, MSE designed the study; ZA, AYB, HO collected literature and typed the manuscript. EA supervised and collected literature. The author(s) read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Pharmaceutical Botany, Istanbul University Faculty of Pharmacy, 34116 Istanbul, Turkey. 2Department of Pharmaceutical Technology, Istanbul University Faculty of Pharmacy, 34116 Istanbul, Turkey. 3Department of Medical Pharmacology, Istanbul University Faculty of Medicine, 34116 Istanbul, Turkey.

Received: 3 January 2021 Accepted: 1 October 2021

Published online: 11 October 2021

References

1. Heinrich M, Edward S, Moerman DE, Lecent M. Ethnopharmacological field studies: a critical assessment of their conceptual basis and methods. J Ethnopharmacol. 2009;124(1):1–17. https://doi.org/10.1016/j.jep.2009.03.043.

2. Ramsay JR, Suhbier A, Aylward JH, Ogbourne S, Cozzi SJ, Poulten MG, et al. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Br J Dermatol. 2011;164(6):633–6. https://doi.org/10.1111/j.1365-2133.2010.09792.x.

3. Williams AC. Skin Structure, Function, and Permeation. In: Benson HA, Watsonson AC, editors. Transdermal and topical drug delivery: principles and practice. Hoboken; Wiley, 2012. p. 3–22.

4. Hajir T, Gontijo JRV, Hanifin JM. New and developing therapies for atopic dermatitis. An Bras Dermatol. 2018;93(1):104–7. https://doi.org/10.5935/abd106841.2018762.

5. Hoffmann J, Grendrich F, Schempp CM, Wölfle U. New herbal biomedicines for the topical treatment of dermatological disorders. Biomedicines. 2020;8(2).27. https://doi.org/10.3390/biomedicines8020027.

6. Uğulu İ, Baslar S, Yorek N, Dogan Y. The investigation and quantitative ethnobotanical evaluation of medicinal plants used around Izmir province. Turkey J Med Plant Res. 2009;3:345–67.

7. Fakir H, Korkmaz M, Güller B. Medicinal plant diversity of Western Mediterranean region in Turkey. JABS. 2009;3:30–40.

8. Tetik F, Çivelek S, Cakılıçoglu U. Traditional uses of some medicinal plants in Malatya (Turkey). J Ethnopharmacol. 2013;146(1):331–6. https://doi.org/10.1016/j.jep.2012.12.054.

9. Ezer N, Ansan O. Folk Medicines in Merzifon (Amasya, Turkey). Turk J Bot. 2006;30:223–30.

10. Oztürk M, Dinc M, Nizip (Aksaray) Bölgesi’nin Etnobotanik Özellikleri. 5. Sist Bot Dergisi. 2005;12:93–102.

11. Sezik E, Yesilada E, Honda G, Takaishi Y, Takeda Y, Tanaka T. Traditional medicine in Turkey X. folk medicine in Central Anatolia. J Ethnopharmacol. 2001;75(2-3):95–115. https://doi.org/10.1016/S0378-8741(00)00599-8.

12. Ugurcu E, Seccmen O. Medicinal plants popularly used in the villages of Yunt Mountain (Manisa-Turkey). Fitoterapia. 2008;79(2):126–31. https://doi.org/10.1016/j.fitote.2007.07.016.

13. Yazıcıoğlu E, Trabzon ilinde ilâc ve gada olarak kullanılan bitkiler: Yüksek Lisans Tezi. İstanbul Üniversitesi Sağlık Bilimleri Enstitüsü Fıratlı Bakmak Botanik Bitihim Dalı; 1993 (in Turkish). Erişim adresi https://tez.yok.gov.tr/UlusalTezMerkezi/tezSorguSonucYeni.jsp.

14. Bulut-Emre G. Bayramoğlu (Canakkale) bölgesinde etnobotanik araştırmalar. Marmara Sağlık Bilimleri Enstitüsü Fıratlı Bakmak Botanik Anabilim Dalı Doktora Tezi, 2008 (in Turkish). Erişim adresi https://tez.yok.gov.tr/UlusaTezMerkezi/tezDetay.jsp?id=be694fUkoxawtH535nStrWfW6a=872cRSTKumeSxWReA LSmg.

15. Kultur S. Medical plants used in Kırklareli province (Turkey). J Ethnopharmacol. 2007;111(2):341–6. https://doi.org/10.1016/j.jep.2006.11.035.

16. Keklik T. Konya il hâlî ilâc. Yüksek Lisans Tezi; İstanbul Üniversitesi Sağlık Bilimleri Enstitüsü Fıratlı Bakmak Botanik Anabilim Dalı; 1990 (in Turkish). Erişim adresi https://tez.yok.gov.tr/UlusaTezMerkezi/tezSorguSonucYeni.jsp.

17. Türkcan S, Mayer H, Özydın S, Tumen G. Ordu ilinde ve Çevresinde Yetişen Bazı Bitkilerin Etnobotanik Özellikleri. Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi. 2009;10:162–74. (in Turkish).

18. Demirci S, Özhataý N. Local names of some plants in Andirin, Kahramanmaraş. J Pharm Istanbul Univ. 2012;42:33–42 (in Turkish).

19. Köyüt M, Yalova ilinde etnobotanik bir araştırma. Yüksek Lisans Tezi; İstanbul Üniversitesi Sağlık Bilimleri Enstitüsü Fıratlı Bakmak Botanik Anabilim Dalı; 2005 (in Turkish). Erişim adresi https://tez.yok.gov.tr/UlusaTezMerkezi/tezSorguSonucYeni.jsp.

20. Ecevit Ç. Catalca ilinde etnobotanik bir araştırma. Yüksek Lisans Tezi; İstanbul Üniversitesi Sağlık Bilimleri Enstitüsü Fıratlı Bakmak Botanik Anabilim
Buzzi M, de Freitas F, Winter M. A prospective descriptive study to assess the clinical benefits of using Calendula officinalis extracts for the topical treatment of diabetic foot ulcers. Ostomy Wound Manage. 2016; 62(3):8–24.

Schneider F, Danski MT, Vayego SA. Usage of Calendula officinalis in the prevention and treatment of radiodermatitis: a randomized double-blind controlled trial. Rev Esc Enferm USP. 2015;49(2):221–8. https://doi.org/10.1590/2446-6970.2014.00010006.

Pommer G, Gomez F, Suryah MP, D’Hombres A, Carie C, Montabaro X. Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. J Clin Oncol. 2004;22(8):1447–53. https://doi.org/10.1200/JCO.2004.07.063.

Omidian M, Hemmati AA, Farajzade H, Houshandi G, Sattari A, Kouchak M. Priority of 5% quince seed cream versus 1% phenytoin cream in the healing of skin ulcers: a randomized controlled trial. Jundishapur J Nat Pharm Prod. 2015;10:e4590. https://doi.org/10.17795/jjnpp-24590.

Abbasi S, Kamalinejad M, Babaei D, Shams S, Sadr Z, Ghayasi M, et al. A new topical treatment of atopic dermatitis in pediatric patients based on Ficus carica L. (fig). A randomized, placebo-controlled clinical trial. Complement Ther Med. 2017;35:85–91. https://doi.org/10.1016/j.ctm.2017.10.005.

Javidnia K, Daragheh S, Samani SM, Nasiri A. Antioxidant activity of fennel (fruits of Foeniculum vulgare) extract. A double-blind placebo controlled study. Phytomedicine. 2003;10(6–7):455–8. https://doi.org/10.1078/0944-7113-003186.

Akba O, Rabei K, Kashi Z, Bahar A, Khorasani EZ, Kosaryan M, et al. The effect of fennel (Foeniculum vulgare) gel 3% in decreasing hair thickness in idiopathic mild to moderate hirsutism, a randomized placebo controlled clinical trial. Carpathian J Intern Med. 2011;4(1):26–9.

Schempp CM, Windeck T, Hoxel S, Simon JC. Topical treatment of atopic dermatitis with St. John’s wort cream—a randomized, placebo controlled, double blind half-side comparison. Phytomedicine. 2003;10:31–7. https://doi.org/10.1078/0944-7113-00306.

Hajhashem M, Ghanbari Z, Movahedi M, Rafieian M, Keivani A, Haghflahi F. The effect of Achillea millefolium and Hypericum perforatum ointments on epistaxis wound healing in impregnous women. J Matern Fetal Neonatal Med. 2018;31(1):63–9. https://doi.org/10.1080/14737104.2016.1275549.

Lavagna SM, Secchi D, Chimenti P, Bonsignore L, Ottaviani A, Bizzarri B. Efficacy of Hypericum and Calendula ointments in the epitelization of surgical wounds in childbirth with caesarean section. Farmaco. 2001;56(5–7): 451–3. https://doi.org/10.1016/S0367-326X(00)00277-X.

Najafzadeh P, Hashemian F, Maniouni P, Fanshi S, Surmaghi MS, Chalangari R. The evaluation of the clinical effect of topical St. John’s wort (Hypericum perforatum L.) in plaque type psoriasis vulgaris: a pilot study. Australas J Dermatol. 2012;53(1):131–5. https://doi.org/10.1111/j.1440-0960.2012.00877.x.

Samadi S, Khadvizadeh T, Emami A, Moosavi NS, Tafaghodi M, Behnam HR. The effect of Hypericum perforatum on the wound healing and scar of cesarean. J Altern Complement Med. 2010;16(1):113–7. https://doi.org/10.1089/acm.2009.0317.

Vakilian K, Atarha M, Behkadi R, Chamani R. Healing advantages of lavender essential oil during epistaxis recovery: a clinical trial. Complement Ther Clin Pract. 2011;17(1):50–3. https://doi.org/10.1016/j.ctcp.2010.05.006.

Koychev R, Alken KG, Durdarov S. Balm mint extract (Lo701) for topical treatment of recurring herpes labialis. Phytomedicine. 1999;6(4):225–30. https://doi.org/10.1016/S0944-7113(99)00013-0.

Kim KY, Jang HH, Lee SN, Kim YS, Lee S. Effects of the myrtle essential oil on the acne skin—clinical trials for Korean women. Biomed Dermatol. 2018;2(1): 28. https://doi.org/10.1186/s19702-018-0038-3.

Kim KT, Jang HH, Lee SN, Kim YS. Effects of the myrtle essential oil on the acne skin—clinical trials for Korean women. Biomed Dermatol. 2018;2(1): 28. https://doi.org/10.1186/s19702-018-0038-3.

Kheiri A, Amini S, Javidan AV, Saghafi MM, Khorasani G. The effects of Alkanna tinctoria Tausch on split-thickness skin graft donor site management: a randomized, blinded placebo-controlled trial. BMC Complement Altern Med. 2017;17(1):253. https://doi.org/10.1186/s12906-017-1741-0.

Song T, Kim KH, Lee KW. Randomized comparison of silicone gel and onion extract gel for post-surgical scars. J Obstet Gynaecol. 2018;38(5):702–7. https://doi.org/10.1080/01443615.2017.1400524.

Chung YQ, Kelley L, Marra D, Jiang SB. Onion extract gel versus petrolatum emollient on new surgical scars: prospective double-blinded study. Dermatol Surg. 2006;32(2):193–7. https://doi.org/10.1111/j.1524-475X.2006.00465.x.

Kundakovic T, Milenkovic M, Zlatkovic S, Nikolic V, Nikolic G, Binić I. Treatment of venous ulcers with the herbal-based ointment Herbamedermal®: a prospective non-randomized pilot study. Forsch Komplementmed. 2012; 19(1):26–30. https://doi.org/10.1159/000353578.

Kanchev S, Ohtani T, Uede K, Furukawa F. Clinical effects of undershirts coated with borago oil on children with atopic dermatitis: a double-blind, placebo-controlled clinical trial. J Dermatol. 2007;34(12):811–5. https://doi. org/10.1111/j.1346-8138.2007.00391.x.

Buzzi M, de Freitas F, Winter M. A prospective descriptive study to assess the clinical benefits of using Calendula officinalis Hydroglycopic extract for...
59. Teker AM, Korkut AY, Kahya V, Gedikli O. Prospective, randomized, controlled clinical trial of Ankaferd blood stopper in patients with acute anterior epistaxis. Eur Arch Otorhinolaryngol. 2010;267(9):1377–81. https://doi.org/10.1007/s00405-010-1208-0.

60. Teker AM, Korkut AY, Gedikli O, Kahya V. Prospective, controlled clinical trial of Ankaferd blood stopper in children undergoing tonsillectomy. Int J Pediatr Otorhinolaryngol. 2009;73(12):1742–5. https://doi.org/10.1016/j.ijporl.2009.09.029.

61. Gorgulu S, Nergaz T, Sipahi I. Ankaferd blood stopper as a new strategy to avoid early complications after transradial procedures: a randomized clinical trial. J Interv Cardiol. 2018;31(4):511–7. https://doi.org/10.1111/joc.12514.

62. Concato J. Observational versus experimental studies: what’s the evidence for a hierarchy? NeuroRx. 2004;1(3):341–7. https://doi.org/10.1602/neurorx.1.3.341.

63. Murad MH, Asi N, Alawas M, Alahdab F. New evidence pyramid. Evid Based Med. 2016;21(4):125–7. https://doi.org/10.1136/ebmed-2016-110401.

64. Jabbari M, Daneshfard B, Emteazy M, Khiveh A, Hashempur MH. Biological effects and clinical applications of dwarf elder (Sambucus ebulus L): a review. J Evid Based Complement Altern Med. 2017;22(4):996–1001. https://doi.org/10.1177/2156587217701322.

65. Hosseinkhani A, Falahat-zadeh M, Racoof E, Zanthenas MM. An evidence-based review on wound healing herbal remedies from reports of traditional Persian medicine. J Evid Based Complement Altern Med. 2017;22(2):334–43. https://doi.org/10.1177/2156587216654773.

66. Pereira RF, Bártolo PJ. Traditional therapies for skin wound healing. Adv Wound Care. 2016;5(5):208–29. https://doi.org/10.1089/wound.2013.0506.

67. Shedoeva A, Leavestley D, Upton Z, Fan C. Wound healing and the use of medicinal plants. Evid Based Complement Alternat Med. 2019;2684108:1–30. https://doi.org/10.1155/2019/2684108.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.